https://www.clinicaltrials.gov/ct2/show/NCT03627065
A Study of INCB050465 in Primary Sjögren’s Syndrome
Brief Summary:
The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren’s syndrome (SS).
Condition or disease Intervention/treatment Phase
Primary Sjögren’s Syndrome
Drug: Parsaclisib
Phase 2
Study Design
Go to sections
Study Type : Interventional
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjögren’s Syndrome
Actual Study Start Date : September 24, 2018
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : January 31, 2020
